SCHEMBL5714741

SCHEMBL5714741

O=C(Oc1ccc(N2C(=O)C3CCCCC3C2=O)cn1)N1CCN(c2ccc(F)cn2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 10/20 0.49
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GPR119 Q8TDV5 1/20 0.38
HPGD P15428 3/20 0.38
ALDH1A1 P00352 2/20 0.38
ALOX15 P16050 1/20 0.38
GAA P10253 1/20 0.38
TACR3 P29371 1/20 0.38
ME2 P23368 1/20 0.38
ME1 P48163 1/20 0.38
ME3 Q16798 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714872 0.89 TACR3 (0.41) HRH3GPR119HPGDALDH1A1GAA
SCHEMBL5714870 0.89 HRH3 (0.46) HRH3KMT2AGPR119HPGDALDH1A1
SCHEMBL5715183 0.88 SMN1; SMN2 (0.52) HRH3MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL5715200 0.88 HRH3 (0.46) HRH3MEN1KMT2AHPGDALDH1A1
SCHEMBL5715090 0.86 ALDH1A1 (0.47) HRH3MEN1KMT2AGPR119HPGD
SCHEMBL5904319 0.85 KMT2A (0.41) HRH3MEN1KMT2AGPR119HPGD
SCHEMBL5714905 0.81 ALDH1A1 (0.39) HRH3MEN1KMT2AHPGDALDH1A1
SCHEMBL5715522 0.81 HRH3 (0.44) HRH3GPR119HPGDALOX15TACR3
SCHEMBL5690018 0.74 ALDH1A1 (0.37) HRH3MEN1KMT2AGPR119HPGD
SCHEMBL5714590 0.74 MGLL (0.37) HRH3MEN1KMT2AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HRH3 1098/4885MEN1 3380/4885KMT2A 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.